Updated Jul 16, 2026
KIRSKE DAVID has filed 2 SEC Form 4 filings across 1 company in the last 90 days — selling. Lifetime open-market sales: $109K.
David Kirske serves as the Chief Financial Officer at X4 Pharmaceuticals, Inc., a biopharmaceutical company focused on developing therapies for rare immune system diseases. He has been involved in the financial operations of the company, as indicated by his role and SEC filings.
| Role | Chief Financial Officer |
|---|---|
| Notability | 20/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-07-01 | XFOR | X4 Pharmaceuticals, Inc | S — Open-market sale | 8.5K | $4.26 | $36K |
| 2026-05-13 | XFOR | X4 Pharmaceuticals, Inc | S — Open-market sale | 17.0K | $4.29 | $73K |
| 2025-08-12 | XFOR | X4 Pharmaceuticals, Inc | A — Grant or award | 193.3K | $0.00 |
David Kirske serves as the Chief Financial Officer at X4 Pharmaceuticals, Inc., a biopharmaceutical company focused on developing therapies for rare immune system diseases. He has been involved in the financial operations of the company, as indicated by his role and SEC filings.…
2 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($109K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live KIRSKE DAVID profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.